Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Tele-rehabilitation Program in People With Multiple Sclerosis and Mild Disability (MS-FatigueCARE)

2 de novembro de 2026 atualizado por: IRCCS San Raffaele Roma

Exploring Mechanisms and Fatigue Management Strategies Through a Tele-rehabilitation Program in People With Multiple Sclerosis and Mild Disability

MS-FatigueCARE is a prospective, multicenter study aimed at investigating the mechanisms underlying fatigue in people with multiple sclerosis (MS) and mild disability, and at evaluating the efficacy of a personalized home-based telerehabilitation program. Fatigue is one of the most debilitating symptoms of MS and can significantly impact daily activities and quality of life, even in individuals with low levels of neurological disability. Current assessment relies primarily on patient-reported measures, highlighting the need for objective and sensitive fatigue biomarkers.

The study comprises two complementary phases. Phase 1 is a cross-sectional observational study comparing people with relapsing-remitting MS and mild disability (EDSS score 0-3.5) with healthy controls. The objective is to investigate the relationship between perceived fatigue and objective physiological and motor parameters, focusing specifically on oxygen consumption (VO₂), the metabolic cost of walking (CW), postural control, and gait-related parameters. In participants with MS, the potential association between fatigue and Epstein-Barr virus (EBV) serological status or reactivation will also be examined.

Phase 2 is a single-blind, randomized controlled crossover study involving MS participants who completed Phase 1. Participants will be randomly assigned to either a six-week multidomain telerehabilitation program-based on non-immersive virtual reality and "serious games"-or a self-managed therapeutic education program. The telerehabilitation intervention integrates motor, cognitive, and cardiorespiratory exercises to be performed at home four times a week for 60 minutes, with remote monitoring by rehabilitation professionals. After a six-week washout period, participants will switch to the alternative intervention. The primary outcome is the energy cost of walking, measured during the 6-Minute Walking Test. Secondary outcomes include subjective fatigue, cognitive and psychological functioning, walking and balance performance, quality of life, usability, and treatment adherence, as well as instrumental measures of VO₂/VCO₂, postural control, and lower-limb kinematics.

Overall, MS-FatigueCARE aims to identify objective markers of fatigue and determine whether a personalized, multi-domain telerehabilitation approach can reduce fatigue and improve functional outcomes and quality of life for people with MS, while fostering accessible and continuous rehabilitative care.

Visão geral do estudo

Status

Ativo, não recrutando

Condições

Intervenção / Tratamento

Tipo de estudo

Intervencional

Inscrição (Estimado)

120

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • Italy
      • Roma, Italy, Itália, 00163
        • IRCCS San Raffaele

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 65 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Sim

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Individuals diagnosed with relapsing-remitting MS (RRMS);
  • Age between 18 and 65 years;
  • EDSS (Expanded Disability Status Scale) score between 0 and 3.5;
  • No fixed or stable pharmacological therapy;
  • Three months since the last relapse;
  • Self-reported persistent fatigue with a significant impact on daily life, assessed using a Visual Analogue Scale (VAS) for fatigue impact, with a score >20 indicating moderate to severe fatigue;
  • Ability to understand and sign the informed consent for the study;
  • Ability to perform the study procedures.

Exclusion Criteria:

  • Evidence of clinical relapses and/or steroid treatment (within 6 months prior to study start);
  • Severe cardiorespiratory disease;
  • Individuals diagnosed with major depression (DSM-5);
  • Severe visual impairment;
  • Severe joint and/or bone disorders interfering with balance and gait (based on clinical judgment);
  • Recent Botulinum Toxin injection in the affected upper limb, or such an injection planned for the duration of the study;
  • Interruption of treatment for 1 week or 5 consecutive sessions;
  • Participation in other interventional studies aimed at fatigue management;
  • Inability to adhere to the exercise program due to poor compliance;

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Outro
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição cruzada
  • Mascaramento: Solteiro

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Telerehabilitation First (Group A)

Participants will first receive a 6-week multidomain home-based telerehabilitation program, delivered 4 times per week in 60-minute sessions. The intervention includes motor, cognitive, and cardiorespiratory exercises based on non-immersive virtual reality and serious games, with remote monitoring by rehabilitation professionals. After a 6-week washout period, participants will cross over to the self-managed therapeutic educational program for 6 weeks.

A 6-week multidomain home-based telerehabilitation program combining motor, cognitive, and cardiorespiratory exercises delivered through non-immersive virtual reality and serious games. Participants will perform four 60-minute sessions per week, for a minimum of 20 sessions. The program will be personalized according to individual clinical characteristics and needs. Exercises will be performed at home using a dedicated Home-Kit with connected sensors providing visual and auditory biofeedback. Rehabilitation professionals will remotely monitor participants' performance and progress and progressively adapt exercise difficulty when appropriate.

A 6-week self-managed therapeutic educational program including exercises similar to those proposed in the telerehabilitation program. The program will be adapted for people with multiple sclerosis and matched to the telerehabilitation intervention in terms of intensity and duration. Participants will perform the activities independently at home and will record completed activities in a weekly diary.

Comparador Ativo: Educational Program First (Group B)

Participants will first receive a 6-week self-managed therapeutic educational program including exercises similar to those provided in the telerehabilitation program and matched for treatment intensity and duration. Activities will be performed independently and recorded in a weekly diary. After a 6-week washout period, participants will cross over to the 6-week multidomain home-based telerehabilitation program.

A 6-week multidomain home-based telerehabilitation program combining motor, cognitive, and cardiorespiratory exercises delivered through non-immersive virtual reality and serious games. Participants will perform four 60-minute sessions per week, for a minimum of 20 sessions. The program will be personalized according to individual clinical characteristics and needs. Exercises will be performed at home using a dedicated Home-Kit with connected sensors providing visual and auditory biofeedback. Rehabilitation professionals will remotely monitor participants' performance and progress and progressively adapt exercise difficulty when appropriate.

A 6-week self-managed therapeutic educational program including exercises similar to those proposed in the telerehabilitation program. The program will be adapted for people with multiple sclerosis and matched to the telerehabilitation intervention in terms of intensity and duration. Participants will perform the activities independently at home and will record completed activities in a weekly diary.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Cost of walking - CW
Prazo: Day 1 (T0 - baseline) ; After 6 weeks from day 1 (T1 - end of treatment)

Cost of Walking (CW) represents the energy expenditure required to walk at a given speed and provides an index of walking efficiency. It will be assessed through cardiopulmonary exercise testing (CPET), based on oxygen consumption (VO₂), carbon dioxide production (VCO₂), and other metabolic parameters. Lower CW values indicate greater walking efficiency.

Day 1 (T0 - baseline) ; After 6 weeks from day 1 (T1 - end of treatment)

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Fatigue Severity Scale (FSS)
Prazo: Day 1 (T0 - baseline) ; After 6 weeks from day 1 (T1 - end of treatment)

The Fatigue Severity Scale (FSS) is a standardized self-reported questionnaire used to assess the severity of fatigue and its impact on daily activities and functional performance. It consists of 9 items, each rated on a 7-point Likert scale (1 = strongly disagree; 7 = strongly agree). The total score ranges from 9 to 63, with higher scores indicating greater fatigue severity and a more significant impact on daily functioning. The FSS is widely used in clinical practice and research to evaluate fatigue and monitor changes over time.

Day 1 (T0 - baseline) ; After 6 weeks from day 1 (T1 - end of treatment)
Modified Fatigue Impact Scale (MFIS)
Prazo: Day 1 (T0 - baseline) ; After 6 weeks from day 1 (T1 - end of treatment)

The Modified Fatigue Impact Scale (MFIS) is a standardized self-reported questionnaire used to assess the impact of fatigue on daily functioning and quality of life. It consists of 21 items covering three main domains: physical, cognitive, and psychosocial functioning. Each item is rated on a 5-point Likert scale ranging from 0 (never) to 4 (almost always). The total score ranges from 0 to 84, with higher scores indicating a greater impact of fatigue on daily activities. The MFIS is widely used in clinical practice and research to evaluate fatigue-related limitations, particularly in patients with neurological disorders, and to monitor changes in fatigue impact over time.

Day 1 (T0 - baseline) ; After 6 weeks from day 1 (T1 - end of treatment)
Visual Analog Scale (VAS)
Prazo: Day 1 (T0 - baseline) ; After 6 weeks from day 1 (T1 - end of treatment)

The Visual Analog Scale (VAS) is a standardized self-reported assessment tool used to measure the intensity of subjective symptoms, particularly pain. It typically consists of a 100-mm horizontal line, anchored by two endpoints representing "no pain" (0) and "worst imaginable pain" (100). Participants are asked to mark the point that best reflects their perceived pain intensity. The score ranges from 0 to 100 mm, with higher scores indicating greater pain intensity. The VAS is widely used in clinical practice and research to assess pain severity, evaluate treatment effectiveness, and monitor changes in symptom intensity over time.

Day 1 (T0 - baseline) ; After 6 weeks from day 1 (T1 - end of treatment)
Montreal Cognitive Assessment Test (MoCa)
Prazo: Day 1 (T0 - baseline) ; After 6 weeks from day 1 (T1 - end of treatment)

The Montreal Cognitive Assessment (MoCA) is a standardized cognitive screening tool used to assess global cognitive function and detect mild cognitive impairment. It evaluates several cognitive domains, including attention, concentration, executive functions, memory, language, visuospatial abilities, abstraction, calculation, and orientation. The total score ranges from 0 to 30, with higher scores indicating better cognitive performance. A score below 26 is commonly considered suggestive of cognitive impairment, although interpretation should account for age, education, and clinical context. The MoCA is widely used in clinical practice and research to identify cognitive deficits and monitor changes in cognitive function over time, particularly in patients with neurological disorders.

Day 1 (T0 - baseline) ; After 6 weeks from day 1 (T1 - end of treatment)
Symbol Digit Modalities Test (SDMT)
Prazo: Day 1 (T0 - baseline) ; After 6 weeks from day 1 (T1 - end of treatment)

The Symbol Digit Modalities Test (SDMT) is a standardized neuropsychological assessment tool used to evaluate cognitive processing speed, attention, visual scanning, and working memory. The test requires participants to match geometric symbols with corresponding numbers using a predefined reference key within 90 seconds. It can be administered in written or oral form. The total score represents the number of correct symbol-digit substitutions, with higher scores indicating better cognitive performance. The SDMT is widely used in clinical practice and research to detect cognitive impairment and monitor changes in cognitive processing speed over time, particularly in patients with neurological disorders such as multiple sclerosis.

Day 1 (T0 - baseline) ; After 6 weeks from day 1 (T1 - end of treatment)
Paced Auditory Serial Addition Test (PASAT)
Prazo: Day 1 (T0 - baseline) ; After 6 weeks from day 1 (T1 - end of treatment)

The Paced Auditory Serial Addition Test (PASAT) is a standardized neuropsychological assessment tool used to evaluate sustained and divided attention, working memory, information processing speed, and auditory processing abilities. During the test, participants listen to a sequence of single-digit numbers presented at fixed time intervals and are required to continuously add each new number to the immediately preceding one. The test is commonly administered using 3-second (PASAT-3) or 2-second (PASAT-2) intervals. Performance is assessed by the number of correct responses, with higher scores indicating better cognitive performance. In the commonly used 60-item version, scores range from 0 to 60. The PASAT is widely used in clinical practice and research to detect cognitive impairment and monitor changes in cognitive functioning over time, particularly in patients with neurological disorders such as multiple sclerosis.

Day 1 (T0 - baseline) ; After 6 weeks from day 1 (T1 - end of treatment)
State-Trait Anxiety Inventory (STAI)
Prazo: Day 1 (T0 - baseline) ; After 6 weeks from day 1 (T1 - end of treatment)

The State-Trait Anxiety Inventory (STAI) is a standardized self-reported questionnaire used to assess anxiety levels by distinguishing between state anxiety (temporary anxiety experienced in a specific situation) and trait anxiety (a relatively stable tendency to experience anxiety). It consists of 40 items divided into two subscales of 20 items each: State Anxiety (STAI-S) and Trait Anxiety (STAI-T). Each item is rated on a 4-point Likert scale, with each subscale yielding a total score ranging from 20 to 80. Higher scores indicate greater levels of anxiety. The STAI is widely used in clinical practice and research to evaluate psychological distress, assess anxiety symptoms, and monitor changes in anxiety levels over time, particularly in patients with neurological and chronic conditions.

Day 1 (T0 - baseline) ; After 6 weeks from day 1 (T1 - end of treatment)
Beck Depression Inventory (BDI)
Prazo: Day 1 (T0 - baseline) ; After 6 weeks from day 1 (T1 - end of treatment)

The Beck Depression Inventory (BDI) is a standardized self-reported questionnaire used to assess the severity of depressive symptoms. It consists of 21 items evaluating cognitive, emotional, behavioral, and somatic symptoms associated with depression, including sadness, pessimism, loss of interest, fatigue, and sleep disturbances. Each item is rated on a 4-point scale ranging from 0 to 3, yielding a total score from 0 to 63, with higher scores indicating greater severity of depressive symptoms. The BDI is widely used in clinical practice and research to assess depressive symptomatology, evaluate psychological well-being, and monitor changes in depression severity over time, particularly in patients with neurological and chronic conditions.

Day 1 (T0 - baseline) ; After 6 weeks from day 1 (T1 - end of treatment)
Expanded Disability Status Scale (EDSS)
Prazo: Day 1 (T0 - baseline) ; After 6 weeks from day 1 (T1 - end of treatment)

The Expanded Disability Status Scale (EDSS) is a standardized clinical assessment tool used to evaluate neurological impairment and disability in people with multiple sclerosis (MS). It assesses neurological function across eight Functional Systems, including pyramidal, cerebellar, brainstem, sensory, bowel and bladder, visual, cerebral (mental), and other neurological functions. The total score ranges from 0 to 10 in 0.5-point increments, with 0 indicating a normal neurological examination and 10 representing death due to MS. Lower scores primarily reflect neurological impairment, while higher scores increasingly emphasize walking limitations and dependence on assistance. The EDSS is widely used in clinical practice and research to assess disease severity, monitor disability progression, and evaluate treatment outcomes over time in people with multiple sclerosis.

Day 1 (T0 - baseline) ; After 6 weeks from day 1 (T1 - end of treatment)
6 Minute Walking Test (6MWT)
Prazo: Day 1 (T0 - baseline) ; After 6 weeks from day 1 (T1 - end of treatment)

The 6-Minute Walk Test (6MWT) is a standardized functional assessment tool used to evaluate walking endurance and functional exercise capacity. It measures the total distance walked in meters over a period of 6 minutes, during which participants are instructed to walk as far as possible at a self-selected pace along a standardized walkway. The total distance covered represents the primary outcome measure, with greater distances indicating better functional exercise capacity and walking endurance. The 6MWT is widely used in clinical practice and research to assess functional mobility and monitor changes in walking performance over time, particularly in patients with neurological, cardiovascular, and respiratory disorders.

Day 1 (T0 - baseline) ; After 6 weeks from day 1 (T1 - end of treatment)
Timed Up and Go test (TUG)
Prazo: Day 1 (T0 - baseline) ; After 6 weeks from day 1 (T1 - end of treatment)

The Timed Up and Go (TUG) is a standardized clinical assessment tool used to evaluate functional mobility, dynamic balance, and fall risk. The test measures the time required, in seconds, for a participant to stand up from a chair, walk a distance of 3 meters at a comfortable and safe pace, turn around, walk back to the chair, and sit down. The total completion time represents the primary outcome measure, with shorter times indicating better functional mobility and balance performance. The TUG is widely used in clinical practice and research to assess mobility limitations and monitor changes in functional performance over time, particularly in patients with neurological and musculoskeletal disorders.

Day 1 (T0 - baseline) ; After 6 weeks from day 1 (T1 - end of treatment)
TUG - Dual Task (TUG-DT)
Prazo: Day 1 (T0 - baseline) ; After 6 weeks from day 1 (T1 - end of treatment)

The Timed Up and Go Dual Task (TUG-DT) is a standardized clinical assessment tool used to evaluate functional mobility, dynamic balance, and cognitive-motor interference under dual-task conditions. The test measures the time required, in seconds, for a participant to stand up from a chair, walk a distance of 3 meters, turn around, walk back to the chair, and sit down while simultaneously performing a secondary cognitive task, such as counting backward or verbal fluency. The total completion time represents the primary outcome measure, with shorter times indicating better dual-task mobility performance. The TUG-DT is widely used in clinical practice and research to assess cognitive-motor interactions, identify mobility limitations, and monitor changes in dual-task performance over time, particularly in patients with neurological disorders.

Day 1 (T0 - baseline) ; After 6 weeks from day 1 (T1 - end of treatment)
54-item Multiple Sclerosis Quality of Life (MSQOL-54)
Prazo: Day 1 (T0 - baseline) ; After 6 weeks from day 1 (T1 - end of treatment)

54-item Multiple Sclerosis Quality of Life (MSQOL-54) The 54-item Multiple Sclerosis Quality of Life Questionnaire (MSQOL-54) is a standardized self-reported assessment tool used to evaluate health-related quality of life in patients with multiple sclerosis (MS). It consists of 54 items, combining the 36-item Short Form Health Survey (SF-36) with 18 additional MS-specific items. The questionnaire assesses several domains, including physical functioning, emotional well-being, pain, fatigue, cognitive functioning, social functioning, sexual function, and overall quality of life. Domain scores are transformed to a 0-100 scale, with higher scores generally indicating better health-related quality of life. Two composite scores, the Physical Health Composite and Mental Health Composite, can also be calculated. The MSQOL-54 is widely used in clinical practice and research to assess the impact of multiple sclerosis on daily life, evaluate treatment outcomes, and monitor changes in quality of

Day 1 (T0 - baseline) ; After 6 weeks from day 1 (T1 - end of treatment)

Outras medidas de resultado

Medida de resultado
Descrição da medida
Prazo
Sway area and Center of Pressure (CoP)
Prazo: Day 1 (T0 - baseline) ; After 6 weeks from day 1 (T1 - end of treatment)

These measurements are acquired during a static balance test performed with eyes open and eyes closed; Kistler stabilometric platforms (1000 Hz, Kistler Group, Winterthur, Switzerland) will be used.

Day 1 (T0 - baseline) ; After 6 weeks from day 1 (T1 - end of treatment)
Spatio-temporal parameters
Prazo: Day 1 (T0 - baseline) ; After 6 weeks from day 1 (T1 - end of treatment)

Gait analysis with Inertial Measurement Units (IMUs)

Day 1 (T0 - baseline) ; After 6 weeks from day 1 (T1 - end of treatment)
Epstein-Barr virus (EBV) serological status and reactivation markers
Prazo: Day 1 (T0 - baseline) ; After 6 weeks from day 1 (T1 - end of treatment)

anti-EBV antibodies and EBV DNA quantification

Day 1 (T0 - baseline) ; After 6 weeks from day 1 (T1 - end of treatment)

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Investigador principal: Sanaz Pournajaf, IRCCS San Raffaele Roma

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Publicações Gerais

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

30 de novembro de 2025

Conclusão Primária (Estimado)

1 de novembro de 2028

Conclusão do estudo (Estimado)

1 de abril de 2029

Datas de inscrição no estudo

Enviado pela primeira vez

14 de outubro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

2 de novembro de 2026

Primeira postagem (Real)

9 de novembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

9 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

2 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • 258/SR/24

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .